Sartorius Stedim Biotech ASM elects two new board members 🌟 At today's Annual Shareholders' Meeting Sartorius Stedim Biotech shareholders appointed Cécile Dussart and Chris Nowers as new directors. ➡️ Cécile Dussart brings 30 years of managerial and industry experience, e.g. at the Swiss-listed dermatology group Galderma and leading pharmaceutical companies Roche and Sanofi. At the constituent board meeting, Dussart was elected to the Audit and Sustainability Committee. ➡️ Christopher Nowers is an accomplished biopharma executive with broad experience in cell therapy and the broader pharmaceutical industry, including ONK Therapeutics, Autolus Therapeutics, Kite Pharma, Bristol Myers Squibb, Amgen and Zeneca. Nowers will be a member of the Remuneration and Nomination Committee. The Board thanked Henri Riey, who served on the Board since 2007 and decided not to seek re-election, for his valuable contributions. As of today, the Board is composed of: Joachim Kreuzburg (Chairman), René Fáber (CEO), Pascale Boissel, Susan Dexter, Cécile Dussart, Romaine Fernandes (Director Representing Employees), Anne-Marie Graffin (Lead Independent Director), Lothar Kappich, and Christopher Nowers. The shareholders also approved a dividend of 0.69 euros per share for fiscal 2024, totaling a payout of 67.1 million euros. Read media release: https://lnkd.in/ePAvAi8c #SimplifyingProgress #ASM #Biopharma
All the luck
Congratulations
Executive Leader | Builds Cohesive, High-Performing Organizations | Drives Excellence, Financial Discipline and Success | Enhances Patient Outcomes | Maximizes Value for Healthcare Systems and Investors
1wI am delighted to be joining the Board and look forward to working closely with the Sartorius Stedim Biotech management team in support of the company's continued success.